or Try an Advanced Search...

    Technical Analysis for KYMR - Kymera Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 43.01 -2.36% -1.04
    KYMR closed up 2.82 percent on Wednesday, November 20, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical KYMR trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish -2.36%
    Lower Bollinger Band Walk Weakness -2.36%
    Up 3 Days in a Row Strength -2.36%
    Oversold Stochastic Weakness -2.36%
    NR7 Range Contraction 0.40%
    Lower Bollinger Band Walk Weakness 0.40%
    Inside Day Range Contraction 0.40%
    Lower Bollinger Band Touch Weakness 0.40%
    Oversold Stochastic Weakness 0.40%
    MACD Bearish Centerline Cross Bearish 1.41%
    Older End-of-Day Signals for KYMR ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % 16 minutes ago
    Down 1% 34 minutes ago
    Rose Above Previous Day's High about 1 hour ago
    Up 1% about 1 hour ago
    Up 2% about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    KYMR Chart by TradingView
    Basic chart:

    Profile

    Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Disease Autoimmunity Rheumatoid Arthritis Hematologic Malignancies Atopic Dermatitis Dermatitis Hidradenitis Suppurativa

    Is KYMR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 5 Kymera Therapeutics to Participate in Upcoming November Investor Conferences
    Nov 4 Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report
    Nov 3 Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript
    Nov 1 Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
    Nov 1 Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
    Nov 1 Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
    Nov 1 U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
    Oct 31 Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
    Oct 31 Kymera Therapeutics GAAP EPS of -$0.82 beats by $0.02, revenue of $3.74M misses by $6.6M
    Oct 31 Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
    See more KYMR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 53.27
    52 Week Low 18.89
    Average Volume 424,996
    200-Day Moving Average 40.85
    50-Day Moving Average 47.00
    20-Day Moving Average 47.37
    10-Day Moving Average 46.85
    Average True Range 2.47
    RSI (14) 42.20
    ADX 18.52
    +DI 19.42
    -DI 32.71
    Chandelier Exit (Long, 3 ATRs) 45.81
    Chandelier Exit (Short, 3 ATRs) 48.54
    Upper Bollinger Bands 52.81
    Lower Bollinger Band 41.92
    Percent B (%b) 0.2
    BandWidth 23.00
    MACD Line -0.79
    MACD Signal Line -0.03
    MACD Histogram -0.7649
    Fundamentals Value
    Market Cap 2.62 Billion
    Num Shares 59.4 Million
    EPS -2.86
    Price-to-Earnings (P/E) Ratio -15.40
    Price-to-Sales 46.41
    Price-to-Book 5.59
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 47.06
    Resistance 3 (R3) 46.74 45.42 46.56
    Resistance 2 (R2) 45.42 44.66 45.58 46.39
    Resistance 1 (R1) 44.74 44.18 45.08 45.05 46.22
    Pivot Point 43.42 43.42 43.59 43.58 43.42
    Support 1 (S1) 42.73 42.65 43.08 43.05 41.88
    Support 2 (S2) 41.41 42.18 41.57 41.71
    Support 3 (S3) 40.73 41.41 41.54
    Support 4 (S4) 41.04